Small molecule inhibitors have been developed, such as dual ADAM10 and ADAM17 inhibitor INCB7839/Aderbasib, which is currently being tested in clinical trials for paediatric glioma as well as diffuse large B cell lymphoma (DLBCL) in combination with rituximab, post autologous haematopoietic cell transplant [149,150]. Here, ADAM10 is linked to diffuse large B-cell lymphoma.